Cambio de nombre a Argent BioPharma Limited
2 de abril de 2024
Argent BioPharma Ltd
Cambio de nombre a Argent BioPharma Limited
Argent BioPharma Ltd (Biofarmacia Argenta o de Empresa), an innovative drug discovery company within the biopharmaceutical sector, has formally changed its name from MGC Pharmaceuticals Limited to Argent BioPharma Limited as approved by shareholders at a General Meeting held 18 March 2024.
Change of name to Argent BioPharma Ltd
The name change has been processed by the Australian Securities and Investments Commission and will take effect on the ASX from commencement of trading on Miércoles, abril 3 2024. The Company's ASX code will migrate to RGT.
The name change will have a delayed effective date in the UK due to additional regulatory requirements that can only be met after the effective date on the ASX, the anticipated effective date of change for the UK is 10 de abril de 2024. The Company's new ISIN and TIDM are AU0000326647 y RGT respectivamente.
La dirección del sitio web de la Compañía ahora es www.argentbiopharma.com.
Los accionistas deben tener en cuenta que su participación accionaria no se verá afectada por el cambio de nombre. Los certificados de acciones existentes deben conservarse, ya que seguirán siendo válidos a todos los efectos y no se emitirán nuevos certificados de acciones.
Visión general de la compañía
en un notable milestone signalling the conclusion of its restructuring process, supported by a substantial injection of capital and a comprehensive operational transformation, Argent BioPharma is set to position itself as a significant player in pioneering drug discovery within the biopharmaceutical sector. With dual listings on both the London Stock Exchange and the Australian Stock Exchange, Argent BioPharma is poised to make a considerable impact in advancing medical treatment accessibility, harnessing sophisticated methodologies in PolyPharmacology and Nanotechnology.
As a key pillar of Argent BioPharma's philosophy, the Company embraces PolyPharmacology, an innovative methodology focused on crafting and implementing therapeutics to influence numerous molecular targets simultaneously. This approach plays a pivotal role in effectively tackling the intricacies of multifaceted diseases, thereby establishing a pioneering benchmark in both drug development and therapeutic effectiveness.
Aspectos operacionales destacados
Argent BioPharma is positioned to generate revenue through its Investigational Medicinal Products (IMPs), CannEpil® and CimetrA®, which are accessible to patients through early access schemes in key markets including the UK, USA, and Europe. These initiatives are further supported by real-world data obtained from early access treatments, offering valuable insights into safety and efficacy that bolster clinical trial outcomes.
Argent BioPharma's European research hub is a key asset, playing a crucial role across the drug development continuum from conceptualisation to commercialisation. The hub operates from two distinct manufacturing facilities; one dedicated to clinical trials and early access programmes; and the other geared towards large-scale commercial production. Argent BioPharma adheres rigorously to stringent EU GMP and GDP guidelines.
Portafolio de productos
Argent BioPharma places special emphasis on its product range targeting immunology and neurology, utilising PolyPharmacology to innovate novel treatments. Committed to addressing unmet medical needs, the Company aims to introduce new treatment every four years. Key products include CannEpil® for refractory epilepsy and cerebral palsy, CimetrA® for acute lung injury and ARDS, and CogniCann® for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development.
Roby Zomer, director general y director ejecutivo de Argent BioPharma, comentó: "As Argent BioPharma emerges from MGC Pharma, it is well positioned in the new era in biopharmaceuticals, committed to providing accessible and impactful healthcare solutions on a global scale. This rebranding signifies our commitment to innovation and advancement in the biopharmaceutical landscape. We are excited to leverage our expertise in PolyPharmacology and Nanotechnology to pioneer ground-breaking treatments, addressing unmet medical needs and driving positive change in global healthcare."
-###-
Autorizado para su divulgación por la junta directiva, para más información, comuníquese con:
Biofarmacia Argenta Roby Zömer CEO y Director Gerente +61 8 6382 3390
| Biofarmacia Argenta Rowan Harland Secretaria de Empresa +61 8 6382 3390 |
Asesores de Relaciones Internacionales y Relaciones Públicas del Reino Unido Asesoría IFC Graham Herring/Tim Metcalfe/Zach Cohen +44 203 934 6630 | UK Brokers Capital de Oberón Aimee McCusker / Adam Pollock +44 203 179 5300 |
Sobre Biofarmacia Argenta
Argent BioPharma se dedica a satisfacer necesidades médicas no satisfechas combinando polifarmacología y nanotecnología, aspirando a ser un líder mundial reconocido en el sector biofarmacéutico. Nuestra misión se centra en investigar y desarrollar tratamientos innovadores para problemas de salud en todo el mundo, guiados por principios estratégicos como ser pioneros en avances en ciencias biológicas, garantizar el acceso global, fomentar la innovación continua y esforzarnos por alcanzar el liderazgo en la industria.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.